Loading...
OTCM
FSNUY
Market cap27bUSD
Oct 08, Last price  
11.71USD
1D
-3.94%
1Q
-3.86%
Jan 2017
-39.89%
Name

Fresenius SE & Co KGaA

Chart & performance

D1W1MN
OTCM:FSNUY chart
P/E
19.57
P/S
1.08
EPS
4.27
Div yield, %
2.42%
Shrs. gr., 5y
0.20%
Rev. gr., 5y
-8.81%
Revenues
22.87b
+4.76%
10,776,000,00011,358,000,00012,336,000,00014,164,000,00015,972,000,00016,522,000,00019,508,000,00020,545,000,00023,459,000,00027,995,000,00029,471,000,00033,886,000,00033,530,000,00035,409,000,00036,277,000,00037,077,000,00021,329,000,00021,067,000,00021,833,000,00022,873,000,000
Net income
1.26b
+168.37%
330,000,000410,000,000270,000,000494,000,000622,000,000690,000,000932,000,000988,000,0001,070,000,0001,386,000,0001,560,000,0001,814,000,0002,027,000,0001,883,000,0001,707,000,0001,818,000,0001,372,000,000-594,000,000471,000,0001,264,000,000
CFO
2.70b
+10.13%
1,052,000,0001,296,000,0001,074,000,0001,553,000,0001,911,000,0001,689,000,0002,438,000,0002,320,000,0002,585,000,0003,327,000,0003,574,000,0003,937,000,0003,742,000,0004,263,000,0006,549,000,0005,078,000,0004,198,000,0004,456,000,0002,447,000,0002,695,000,000
Dividend
May 26, 20260.30483 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Fresenius SE & Co. KGaA is a diversified healthcare enterprise delivering a broad spectrum of products and services across multiple sectors, including dialysis, hospital operations, and outpatient medical treatment. Its operations are structured into four main divisions: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. Fresenius Medical Care specializes in supporting individuals suffering from chronic kidney disease, supplying essential products like dialyzers, hemodialysis equipment, and associated disposable items, alongside comprehensive dialysis services. Fresenius Kabi focuses on the therapeutic management and care of acutely and chronically ill patients. Its portfolio encompasses a wide range of offerings, including intravenous generic pharmaceuticals for areas like oncology, pain management, anesthesia, infection control, and critical care. It also provides parenteral and enteral nutritional solutions, infusion fluids, blood volume expanders, and biosimilar drugs targeting autoimmune and oncological conditions. Furthermore, the segment supplies medical devices and consumables vital for administering IV medications, infusion therapies, and clinical nutrition, along with transfusion products for blood component collection and various bodily treatments. Fresenius Helios manages a substantial network of healthcare facilities. In Germany, it operates 90 hospitals, around 130 outpatient clinics, and six prevention centers. Its Spanish presence includes 49 hospitals, 88 outpatient clinics, and approximately 300 risk prevention centers. Additionally, this segment extends its services to fertility treatment, operating 33 dedicated clinics and 39 supplementary locations spanning ten countries across three continents. Fresenius Vamed is dedicated to project management and service provision for hospitals and other healthcare infrastructure. Its comprehensive offerings range from project conception, detailed planning, and complete turnkey construction to ongoing maintenance, technical oversight, and operational administration. Originally established in 1912, the company was previously known as Fresenius SE before adopting its current name, Fresenius SE & Co. KGaA, in January 2011. Its global headquarters are situated in Bad Homburg vor der Höhe, Germany.

Related entities

Subsidiaries (95)
FRESENIUS FINANCE IRELAND II PUBLIC LIMITED COMPANY
Fresenius Finance Ireland Public Limited Company
Fresenius HemoCare Brasil Ltda.
Fresenius HemoCare GmbH
FRESENIUS HEMOCARE ITALIA S.R.L.
Fresenius HemoCare Netherlands B.V.
Fresenius Holding B.V.
Fresenius Kabi (Schweiz) AG
Fresenius Kabi (Singapore) Pte Ltd
Fresenius Kabi AB
Fresenius Kabi Aktiengesellschaft
Fresenius Kabi Asia Pacific Limited
Fresenius Kabi Australia Pty Limited
Fresenius Kabi Austria GmbH
Fresenius Kabi Brasil Ltda.
FRESENIUS KABI BUSINESS SERVICES SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA
Fresenius Kabi Canada Ltd.
Fresenius Kabi Chile Ltda.
Fresenius Kabi Colombia SAS
Fresenius Kabi Compounding, LLC

Key people

Chairman of the Management Board · since 2022
Independent Deputy Chairman of the Supervisory Board · since 2015
Pierluigi Antonelli
Member of the Management Board, Chief Executive Officer - Fresenius Kabi · since 2023
Chief Financial Officer, Member of the Management Board · since 2022
Robert Moeller
Member of the Management Board, Chief Executive Officer of Fresenius Helios · since 2023
Michael Moser
Member of the Management Board, Responsible for Legal, Compliance, Risk Management, ESG, Human Resources, Corporate Audit and Fresenius Vamed · since 2023
Bernd Behlert
Independent Member of the Supervisory Board, Employee Representative · since 2018
Oscar De Paco
Independent Member of the Supervisory Board · since 2016
Grit Genster
Independent Deputy Chairman of the Supervisory Board · since 2020
Wolfgang Kirsch
Independent Chairman of the Supervisory Board · since 2021
Iris Loew-Friedrich
Independent Member of the Supervisory Board · since 2016
Holger Michel
Independent Member of the Supervisory Board, Employee Representative · since 2023
Independent Member of the Supervisory Board · since 2022
D. Michael Albrecht
Independent Member of the Supervisory Board · since 2010
Alberto Franganillo
Member of the Supervisory Board, Employee Representative · since 2025
Gerd Krick
Honorary Chairman of the Supervisory Board · since 2021
Frauke Lehmann
Independent Member of the Supervisory Board, Employee Representative · since 2016
Independent Member of the Supervisory Board · since 2022
IPO date
Dec 18, 1986
Employees
315,233
Domiciled in
DE
Incorporated in
DE
Headquarters & legal address
Else-Kröner-Straße 1
Bad Homburg vor der Höhe, HE 61352
DE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT